જ્યુબિલેન્ટ ફાર્મોવા શેર કિંમત

The CDMO Sterile Injectables segment saw a standout 38% revenue increase to 1,755 crore after launching a third fill-and-finish line in Spokane, Washington

• બિઝનેસ લાઇન
• 1 દિવસ 1 કલાક પહેલાં

Pharmaceuticals company Jubilant Pharmova announced Q4FY26 & FY26 results Consolidated Financial Highlights: Quarterly Performance: Total Revenue from Operations: Stood at Rs 22,900 million in Q4FY26, representing a YoY growth of 18.73% from Rs 19,288 million in Q4FY25 and a QoQ increase of 7.89% from Rs 21,225 million in Q3FY26. Total Income: Reached Rs 23,137 million in Q4FY26, up 19.22% YoY from Rs 19,407 million and up 7.97% QoQ from Rs 21,430 million. Profit Before Tax: For Q4FY26 was Rs 1,760 million, a decrease of 14.56% YoY from Rs 2,060 million and a significant QoQ increase of 88.44% from Rs 934 million. Net Profit: Stood at Rs 1,193 million in Q4FY26, compared to Rs 1,513 million in Q4FY25 (YoY decrease of 21.15%) and Rs 558 million in Q3FY26 (QoQ increase of 113.80%). Total Comprehensive Income: For Q4FY26 was Rs 4,012 million, significantly higher than Rs 1,467 million in Q4FY25 and Rs 1,182 million in Q3FY26. Annual Performance (FY26 vs. FY25): Total Revenue from Operations: Grew to Rs 82,796 million in FY26, a YoY increase of 14.45% from Rs 72,345 million in FY25. Total Income: For FY26 was Rs 83,456 million, up 14.46% YoY from Rs 72,913 million. Profit Before Tax: For FY26 stood at Rs 6,141 million, reflecting a YoY decline of 37.38% from Rs 9,806 million in FY25 (FY25 profit was influenced by higher exceptional gains). Net Profit: In FY26 reached Rs 3,975 million, a YoY decrease of 65.02% from Rs 11,363 million in FY25. Total Comprehensive Income: For the full year FY26 was Rs 9,433 million, compared to Rs 9,213 million in FY25. Standalone Financial Highlights: Quarterly Performance (Q4FY26 vs. Q4FY25): Total Revenue from Operations: For Q4FY26 was Rs 703 million, up 15.82% YoY from Rs 607 million. Net Profit: For Q4FY26 reached Rs 572 million, compared to Rs 136 million in Q4FY25. Annual Performance (FY26 vs. FY25): Total Revenue from Operations: For FY26 stood at Rs 2,635 million, compared to Rs 2,314 million in FY25. Net Profit: Reached Rs 632 million in FY26, a YoY growth of 229.17% from Rs 192 million in FY25. Business Highlights: Segment-wise Performance (FY26 Consolidated Revenue): Radiopharma: Contributed Rs 36,901 million in FY26, up from Rs 33,880 million in FY25. Allergy Immunotherapy: Contributed Rs 7,957 million in FY26, up from Rs 7,142 million in FY25. CDMO - Sterile Injectables: Contributed Rs 18,125 million in FY26, compared to Rs 13,527 million in FY25. CRDMO: Contributed Rs 12,649 million in FY26, compared to Rs 11,728 million in FY25. Generics: Contributed Rs 7,735 million in FY26, up from Rs 6,853 million in FY25. Dividend Recommendation: The Board of Directors has recommended a final dividend of 500%, i.e., Rs 5 per equity share of face value Re 1 each for the financial year ended March 31, 2026. Sale of API Business: The company completed the sale and transfer of its Active Pharmaceutical Ingredients (API) business as a going concern on a slump sale basis to its wholly-owned subsidiary, Jubilant Biosys Limited, effective September 1, 2025. This business has been classified as "Discontinued Operations" in the standalone results. Exceptional Items (FY26): Gain of Rs 236 million on the sale of assets of a ceased manufacturing facility in Salisbury, Maryland, USA. Remediation expenses of Rs 535 million related to the suspension of operations at the Montreal, Canada facility. Incremental impact of Rs 133 million (gratuity of Rs 100 million and compensated absences of Rs 33 million) due to the notification of New Labour Codes. Amortization of debt initiation costs of Rs 96 million on prepayment of a term loan. Impairment of investment in an associate amounting to Rs 64 million. Audit Opinion: The statutory auditors have issued an Audit Report with an unmodified opinion on the audited financial results (standalone and consolidated) for the year ended March 31, 2026. Result PDF

• ટ્રેન્ડલાઇન
• 1 દિવસ 4 કલાક પહેલાં

જુબિલેન્ટ ફાર્મોવા શેર: નેશનલ સ્ટૉક એક્સચેન્જ (એનએસઈ) પર સ્ક્રિપ 4.4 ટકાથી 931 સુધી ઘટી ગઈ છે

• બિઝનેસ સ્ટાન્ડર્ડ
• 3 મહિના 2 અઠવાડિયા પહેલાં